



## UNITED STATES PATENT AND TRADEMARK OFFICE

FEB 10 2005

Commissioner for Patents  
United States Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

In re Application of :  
Suzanne Benedict et al :  
Serial No. 10/754,171 :  
Filed: January 9, 2004 :  
For: TRICYCLIC COMPOUNDS PROTEIN :  
KINASE INHIBITORS FOR ENHANCING :  
THE EFFICACY OF ANTI-NEOPLASTIC :  
AGENTS AND RADIATION THERAPY :

NOTICE OF WITHDRAWAL  
FROM ISSUE  
UNDER 37 CFR 1.313(b)

The purpose of this communication is to inform you that the above-identified application is being withdrawn from issue pursuant to 37 CFR 1.313.

The application is being withdrawn to permit reopening of prosecution. The reasons therefore will be communicated to you by the examiner.

PTO records reveal that the issue fee has not been paid. If the issue fee has been submitted, the applicant may request a refund or may request that the fee be credited to a deposit account. However, applicant may wait until the application is either again found allowable or held abandoned. If the application is allowed, upon receipt of a new Notice of Allowance and Issue Fee Due, applicant may request that the previously submitted issue fee be applied toward payment of the issue fee in the amount identified on the new Notice of Allowance and Issue Fee Due. If the application is abandoned, applicant may request either a refund or a credit to a deposit account.

The application is being forwarded to the examiner for action.

Bruce M. Kisliuk, Director  
Technology Center 1600

AGOURON PHARMACEUTICALS, INC.  
10350 NORTH TORREY PINES ROAD  
LA JOLLA CA 92037

cc: Allowed Files, PK3-910  
Drafting Branch, PK3-910